RT Journal Article
SR Electronic
T1 The new SARS-CoV-2 variant and reinfection in the resurgence of COVID-19 outbreaks in Manaus, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.25.21254281
DO 10.1101/2021.03.25.21254281
A1 He, Daihai
A1 Fan, Guihong
A1 Wang, Xueying
A1 Li, Yingke
A1 Peng, Zhihang
YR 2021
UL http://medrxiv.org/content/early/2021/07/28/2021.03.25.21254281.abstract
AB Manaus, a city of 2.2 million population, the capital of Amazonas state of Brazil was hit badly by two waves of COVID-19 with more than 10,000 severe acute respiratory syndrome deaths by the end of February 2021. It was estimated that the first wave infected over three quarters of the population in Manaus based on routine blood donor data, and the second wave was largely due to reinfection with a new variant named P1 strain. In this work, we revisit these claims, and discuss biological constraints. In particular, we model the two waves with a two-strain model without a significant proportion of reinfections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDH was supported by Collaborative Research Fund (C7123-20G) of the Research Grants Council (RGC) of Hong Kong, China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Neither ethical approval nor individual consent was not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this work were publicly available.